ClinicalTrials.gg
CompletedNCT01865292Updated Oct 19, 2015

Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes

A Phase 1 interventional study of insulin degludec and insulin glargine in Diabetes, Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to male participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2015-10-19.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 69 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 103 studies testing insulin degludec in Diabetes Mellitus — 1 open to participants now, 1 under way, 1 of them phase 3. insulin degludec · Diabetes Mellitus.

Enrollment
66th of 103
40 · median 145
Started
2006
with 2 others
Phase 1
42 of 103
none open now
Registered
68th of 103
by date
Lead sponsor
96 of 103
Novo Nordisk A/S

Among the 103 studies testing insulin degludec in Diabetes Mellitus, this one is the 66th largest by enrollment, is one of 3 that started in 2006, is one of 42 in phase 1, and was the 68th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

1 of the 103 studies testing insulin degludec in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 69 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies testing insulin degludec in Diabetes Mellitus, or all of them as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to compare the pharmacodynamics (the effect of the investigated drug on the body) and pharmacokinetics (the exposure of the trial drug in the body) of insulin degludec (insulin 454), an explorative formulation, not similar to the proposed commercial formulation, with insulin glargine in subjects with type 1 and type 2 diabetes.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Glycosylated () below or equal to 10 procent based on central laboratory results
  • Specific inclusion criteria for subject with type 1 diabetes:
  • Diagnosed with type 1 diabetes mellitus and treated with insulin for at least 12 months prior to screening
  • (BMI) between 18.0 and 27.0 kg/m\^2 (both inclusive)
  • Specific inclusion criteria for subject with type 2 diabetes:
  • Diagnosed with type 2 diabetes mellitus for at least 12 months prior to screening
  • Treated with insulin for the past 3 months prior to screening
  • Body Mass Index (BMI) between 22.0 and 35.0 kg/ m\^2 (both inclusive)

Exclusion criteria

Exclusion Criteria:

  • Subject with a history of significant multiple drug allergies or with a known allergy or suspected allergy to the trial product or any medicine chemically related to the trial product,as judged by the Investigator.
  • Subject with a history of or presence of cancer
  • Any condition that the Investigator and/or Sponsor feels would interfere with study
  • Specific exclusion criteria for subject with type 2 diabetes:
  • Therapy with oral antidiabetic drugs within the past 3 months prior to screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Insulin degludec

    Drug: insulin degludec

  • Active comparator
    Insulin glargine

    Drug: insulin glargine

Interventions

  • Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.

  • Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.

06

What researchers measure

Primary outcomes

  1. Area under the glucose infusion rate curve

    Time frame: 0-24 hours after dosing

Secondary outcomes

  1. Area under the insulin degludec/insulin glargine curve

    Time frame: 0-96 hours after dosing

07

Study locations

1 site
  • Neuss, 41460, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Nov 2006 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2013
First posted
May 30, 2013
Start
Aug 2006
Primary completionActual
Nov 2006
CompletionActual
Nov 2006
Last update
Oct 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01865292
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 30, 2013
Start date
Aug 2006
Primary completion
Nov 2006
Completion
Nov 2006
Last update
Oct 19, 2015

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin degludec

Start the discussion